Dilation and Curettage (D&C) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dilation and curettage (D&C) is a gynaecological surgical procedure in which the cervix is progressively dilated using a series of graduated metal or osmotic dilators, and the endometrial lining of the uterus is then sampled or evacuated using a curette — a spoon-shaped surgical instrument — or a suction cannula.

The procedure serves two distinct clinical purposes:

• Diagnostic D&C: Obtaining a sample of endometrial tissue for histopathological examination to diagnose endometrial hyperplasia, endometrial carcinoma, chronic endometritis, or other intrauterine pathology causing abnormal uterine bleeding (AUB).
• Therapeutic D&C: Evacuating the uterine cavity to remove retained products of conception (RPOC) after miscarriage or incomplete abortion, to manage postpartum haemorrhage from retained placental tissue, or to treat a molar pregnancy.

D&C has been performed in gynaecology for over a century and remains one of the most commonly performed procedures worldwide. However, evidence-based medicine has substantially shifted practice in recent decades. For diagnostic sampling, office-based Pipelle endometrial biopsy (a thin, flexible disposable cannula) has largely replaced sharp curettage as the first-line diagnostic tool, given its equivalent diagnostic accuracy, lower cost, and avoidance of general anaesthesia. For uterine evacuation, manual vacuum aspiration (MVA) and medical management with misoprostol are now preferred over sharp curettage in many international guidelines. Understanding when D&C remains the most appropriate choice — and when safer alternatives exist — is the central clinical question this guide addresses.

D&C is indicated across a range of gynaecological and obstetric conditions, broadly divided into diagnostic and therapeutic categories.

Diagnostic Indications

• Abnormal uterine bleeding (AUB): Particularly in women over 45 years, or in those under 45 with risk factors for endometrial hyperplasia (obesity, PCOS, nulliparity, tamoxifen use, Lynch syndrome), where Pipelle biopsy is insufficient or fails to obtain an adequate tissue sample.
• Postmenopausal bleeding (PMB): When endometrial thickness is ≥4 mm on transvaginal ultrasound, histological sampling is essential to exclude endometrial carcinoma (the most common gynaecological cancer in high-income countries).
• Abnormal endometrial thickening on ultrasound in asymptomatic postmenopausal women, where transvaginal ultrasound shows heterogeneous or thickened endometrium.
• Atypical endometrial cells on cervical cytology requiring tissue diagnosis.

Therapeutic Indications

• Incomplete miscarriage / spontaneous abortion: Removal of retained products of conception (RPOC) causing haemorrhage or infection. This is the most common acute indication globally.
• Missed miscarriage (blighted ovum, fetal demise): Evacuation of retained non-viable pregnancy tissue where medical management (misoprostol) has failed or is declined.
• Gestational trophoblastic disease (molar pregnancy): Suction curettage followed by careful sharp curettage under ultrasound guidance, with post-evacuation beta-hCG monitoring.
• Postpartum haemorrhage from retained placenta: When manual placenta removal at delivery is incomplete, curettage of retained placental fragments may be required.
• Endometrial polyps and submucosal fibroids: Although hysteroscopic resection is preferred (direct visualisation), curettage may be used in settings without hysteroscopy access.

Patient selection for D&C involves careful clinical assessment to ensure the procedure is indicated, that safer alternatives have been considered, and that the patient is medically fit for the chosen anaesthetic.

Clinical Criteria Favouring D&C

• Failed or inadequate office-based endometrial sampling (Pipelle) — occurs in approximately 10–15% of cases due to cervical stenosis, patient discomfort, or insufficient tissue yield.
• Haemodynamically significant or ongoing haemorrhage from RPOC where medical management is inappropriate or has failed.
• Suspected molar pregnancy requiring suction evacuation and careful curettage.
• Cervical stenosis preventing passage of a Pipelle cannula, requiring dilation under anaesthesia.

Patient Fitness Assessment

D&C is a short procedure typically performed under GA or conscious sedation. Pre-operative assessment includes:

• Full blood count (FBC) and group and save — particularly for RPOC procedures where haemorrhage has already occurred.
• Coagulation screen in women with known bleeding disorders or those on anticoagulants.
• Transvaginal or pelvic ultrasound to confirm intrauterine pathology and uterine position (retroversion increases perforation risk).
• Beta-hCG level to confirm or exclude ongoing pregnancy and to provide a baseline for GTD monitoring.

Consent and Specific Risks

Women must be counselled specifically about the risk of intrauterine adhesions (Asherman syndrome), particularly if D&C is being performed for miscarriage. The overall risk after a single curettage for miscarriage is estimated at 1–5%, rising to 20–30% after three or more procedures on the same uterus. This risk should be discussed and documented before obtaining consent.

D&C encompasses several technique variants and is increasingly performed alongside hysteroscopy for direct visualisation of the uterine cavity.

1. Standard Sharp Curettage

The classic technique proceeds as follows:

1. Anaesthesia: GA, conscious sedation (IV midazolam + fentanyl), or paracervical block with LA.
2. Bimanual examination: Uterine position and size confirmed under anaesthesia.
3. Cervical dilation: Progressive passage of Hegar dilators (sizes 1–12) to open the cervical canal sufficiently for the curette (typically to Hegar 8–10 for therapeutic procedures).
4. Curettage: A sharp or blunt metal curette is inserted into the uterine cavity and used with firm, systematic strokes to scrape the endometrial lining, working from the fundus downward in each quadrant. A gritty 'sand-paper' sensation as the curette passes over the endometrium indicates an atrophic or post-evacuated uterus.
5. Specimen collection: Curetted material is collected and sent in formalin for histopathology.

2. Suction Curettage (Electric Vacuum Aspiration, EVA)

A rigid or flexible plastic cannula connected to an electric suction pump is introduced into the uterine cavity after dilation. Suction curettage is faster, more complete, and causes less blood loss than sharp curettage for uterine evacuation. It is the preferred technique for surgical management of first-trimester miscarriage and molar pregnancy in most guidelines (RCOG, ACOG, WHO).

3. Manual Vacuum Aspiration (MVA)

MVA uses a hand-held 60 mL syringe with a cannula to generate negative pressure for uterine evacuation without electric suction equipment. WHO and international reproductive health organisations regard MVA as equivalent in efficacy and safety to EVA for gestations up to 12–14 weeks, and as superior for first-trimester management (less pain with the same anaesthesia, fewer complications, usable in resource-limited settings). MVA can be performed under local anaesthesia alone, avoiding the risks of GA.

4. Hysteroscopy-Guided D&C

Performing D&C under direct hysteroscopic visualisation — rather than blindly — significantly improves diagnostic accuracy. A systematic review (JAMA, 2002) found that blind curettage misses focal endometrial pathology in 10–35% of cases. Hysteroscopy followed by targeted biopsy or resection is now recommended in preference to blind D&C whenever hysteroscopic equipment is available, particularly for diagnosing AUB in postmenopausal women.

5. Osmotic Cervical Priming

For nulliparous women, teenagers, or women with cervical stenosis, osmotic dilators (laminaria tents, Dilapan-S) placed in the cervix 4–12 hours before the procedure allow gradual cervical ripening, reducing the force required for mechanical dilation and lowering the risk of cervical laceration or uterine perforation. Misoprostol (400 mcg vaginally) given 2–4 hours before the procedure is a pharmacological alternative for cervical preparation.

D&C offers definitive treatment or diagnosis in situations where less invasive alternatives have failed or are not applicable.

• Definitive evacuation of retained products of conception: Surgical D&C is the most reliable and fastest method of ensuring complete uterine evacuation in cases of incomplete miscarriage complicated by haemorrhage or sepsis. Completion rates exceed 95% compared to 80–85% for a single dose of misoprostol.
• Histological diagnosis: Curettage provides endometrial tissue for pathological examination, enabling diagnosis of endometrial hyperplasia (with or without atypia), endometrial carcinoma, chronic endometritis, or other intrauterine pathology. For women with complex or atypical hyperplasia, this is a life-saving investigation.
• Control of haemorrhage: Evacuation of retained placenta or pregnancy tissue causing postpartum or post-miscarriage haemorrhage provides rapid haemostasis in situations where medical management has failed.
• Treatment of gestational trophoblastic disease: Suction curettage followed by careful sharp curettage is the definitive treatment for hydatidiform mole. Beta-hCG monitoring after evacuation enables early detection of gestational trophoblastic neoplasia requiring chemotherapy.
• Speed and predictability: For women who have experienced a miscarriage and wish to have certainty of complete evacuation rather than awaiting natural or medical passage, surgical D&C provides a definitive and time-predictable outcome, which can be psychologically important.

D&C is generally a safe procedure, but patients must be counselled about specific complications before consenting.

Uterine Perforation

The uterine wall may be inadvertently perforated by the sound, dilator, or curette. The overall incidence is approximately 0.5–1% for elective procedures and up to 2% in acutely infected or post-abortal uteri. Most perforations are recognised immediately and managed conservatively; laparoscopy is arranged when bowel or vascular injury is suspected. Perforation risk is higher in retroflexed uteri, in postmenopausal women with an atrophic cervix and uterus, and in procedures without ultrasound guidance.

Intrauterine Adhesions (Asherman Syndrome)

The most significant long-term complication of D&C — particularly for uterine evacuation after miscarriage — is the formation of intrauterine adhesions (IUAs), also known as Asherman syndrome. IUAs form when endometrial trauma exposes the underlying myometrium, allowing the anterior and posterior uterine walls to fuse. Clinically, Asherman syndrome presents with hypomenorrhoea or amenorrhoea, cyclical pelvic pain (due to haematometra if the outflow is obstructed), and recurrent pregnancy loss or subfertility. Risk factors include:

• Repeated D&C procedures on the same uterus (risk 20–30% after 3 or more procedures).
• Concurrent endometritis at the time of curettage (risk substantially increased).
• Post-partum curettage — the gravid or recently pregnant uterus has a softer, more vulnerable endometrium.

Treatment of established Asherman syndrome requires operative hysteroscopy to divide adhesions under direct vision, followed by post-operative oestrogen therapy to encourage re-epithelialisation. Fertility outcomes after treatment depend on adhesion severity: mild adhesions have a live birth rate of approximately 70–80%; severe adhesions have rates as low as 20–30%.

Cervical Laceration

Forceful dilation of a tight or unprepared cervix can cause tears at the internal or external os. Minor lacerations are sutured at the time of procedure; significant cervical incompetence is rare.

Infection

Post-operative endometritis or pelvic inflammatory disease occurs in 1–2% of cases. Most units administer prophylactic antibiotics (doxycycline, co-amoxiclav, or azithromycin depending on local protocol) before therapeutic D&C for miscarriage management.

Incomplete Evacuation

Retained products of conception after attempted D&C occur in approximately 1–2% of cases, typically at cornual angles or the utero-tubal junctions that are difficult to access with a rigid curette. Ultrasound performed in the recovery area can confirm uterine cavity clearance.

Anaesthesia Risks

GA and conscious sedation carry small but recognised risks including respiratory depression, aspiration, and allergic reactions. These are minimised by pre-operative assessment and are significantly lower for the short duration of a D&C procedure than for major surgery.

Recovery from D&C is generally rapid, with most women resuming normal activities within 1–2 days. Structured follow-up depends on the indication for the procedure.

Immediate Post-Operative Period

• Light vaginal bleeding or spotting for 1–2 weeks is normal and expected. Use sanitary pads — not tampons — during this period.
• Mild cramping for 24–48 hours, managed with paracetamol and ibuprofen.
• Avoid sexual intercourse, tampons, and swimming for at least 2 weeks, or until bleeding has completely stopped.
• Return to work: Most women with desk jobs return within 1–2 days; those with physically demanding jobs may need 3–5 days.

Follow-Up Investigations

• For diagnostic D&C (AUB): Histopathology results should be reviewed at 1–2 weeks. If endometrial hyperplasia with atypia or carcinoma is found, urgent onward referral is required.
• For miscarriage management: Serum beta-hCG should be checked 2–4 weeks after evacuation to confirm return to non-pregnant levels. A persistently elevated or rising beta-hCG suggests retained GTD (gestational trophoblastic neoplasia) requiring further management.
• For molar pregnancy: Formal registration with a national GTD surveillance programme (e.g., Charing Cross in the UK) and serial beta-hCG monitoring as per protocol.

Return of Menstruation

The first menstrual period typically returns 4–6 weeks after D&C, though this varies. Women who are not planning immediate pregnancy are advised to use contraception from 2 weeks post-procedure. Women trying to conceive after a miscarriage may attempt to do so from the first cycle after the procedure, following NICE guidance (2012, updated 2023) which found no benefit to delaying conception.

Psychological Support

For women who have undergone D&C following miscarriage, access to bereavement counselling and miscarriage support organisations (such as the Miscarriage Association or Tommy's) should be offered. The psychological impact of pregnancy loss is significant and often underestimated by healthcare providers.

The cost of D&C varies substantially by indication, anaesthesia type, and country of treatment. The addition of hysteroscopy to D&C increases both procedural time and cost but significantly improves diagnostic yield.

Key Cost Drivers

• Indication: Emergency D&C for acute haemorrhage from RPOC carries different cost dynamics (emergency theatre fees, blood products, HDU) than an elective diagnostic D&C.
• Anaesthesia: GA is significantly more expensive than MVA performed under local anaesthesia. The choice of anaesthesia is the single largest cost variable in elective cases.
• Concurrent hysteroscopy: Adding hysteroscopy to D&C substantially increases cost (equipment, theatre time) but is increasingly standard of care for diagnostic AUB evaluation.
• Histopathology: Laboratory fees for endometrial tissue processing, including immunohistochemical stains for endometrial hyperplasia or malignancy assessment, add USD 100–500 per specimen.
• Country and healthcare system: Costs vary enormously between countries. Medical tourism for elective gynaecological procedures (such as diagnostic D&C for AUB in perimenopausal women) is well established in India, Thailand, and Eastern Europe.

Approximate Cost Ranges

• United States: Diagnostic D&C (GA + histology) USD 3,000–8,000; D&C + hysteroscopy USD 5,000–12,000
• United Kingdom (private): GBP 1,500–4,000
• India: USD 300–800 (D&C alone); USD 600–1,500 (with hysteroscopy)
• Thailand: USD 700–2,000 (with hysteroscopy)
• Turkey: USD 500–1,500 (with hysteroscopy)

Evidence-based alternatives to D&C have largely replaced it as first-line treatment for many indications. Understanding these alternatives allows women and clinicians to make truly informed decisions.

Manual Vacuum Aspiration (MVA) for Uterine Evacuation

MVA is the WHO-preferred method for surgical management of first-trimester miscarriage and uterine evacuation up to 14 weeks. Evidence from multiple randomised controlled trials and systematic reviews demonstrates that MVA achieves equivalent completeness of evacuation to sharp curettage with less blood loss, fewer complications, greater patient satisfaction, and — crucially — potentially lower risk of intrauterine adhesion formation (because the lighter aspiration trauma is less damaging to the basalis layer of the endometrium). MVA can be performed under local anaesthesia (paracervical block) in an office or clinic setting without theatre facilities.

Medical Management with Misoprostol

Misoprostol (a prostaglandin E1 analogue given vaginally, sublingually, or orally at 800 mcg) causes uterine contractions and cervical ripening, enabling expulsion of RPOC in approximately 80–85% of cases within 48 hours. The WHO, RCOG, and ACOG all recommend offering medical management as the first-line option for first-trimester missed or incomplete miscarriage in haemodynamically stable women. Advantages include avoidance of surgical risk, no anaesthesia, management at home or in a low-resource setting, and preservation of reproductive potential. Disadvantages include higher failure rate than surgery, unpredictable timing and duration of bleeding, and the need for follow-up confirmation of completeness (beta-hCG or ultrasound).

Pipelle Endometrial Biopsy for Diagnostic Purposes

For women requiring endometrial sampling to investigate AUB or PMB, the Pipelle disposable curette can be performed in the outpatient clinic without anaesthesia in the majority of women. Its sensitivity for endometrial carcinoma exceeds 99% in postmenopausal women and is approximately 91% in premenopausal women, making it an excellent first-line diagnostic tool. D&C under GA is reserved for women in whom Pipelle fails (cervical stenosis, inability to tolerate the procedure) or when an adequate sample cannot be obtained.

Hysteroscopy Without D&C

For diagnostic evaluation of the uterine cavity, office hysteroscopy with targeted biopsy is superior to blind D&C for detecting focal pathology (polyps, submucosal fibroids, AIS). Many gynaecology units now perform outpatient hysteroscopy under local anaesthesia as the primary investigation for AUB, reserving GA-based procedures for treatment.

Levonorgestrel Intrauterine System (LNG-IUS / Mirena)

For women with abnormal uterine bleeding due to endometrial hyperplasia without atypia, the LNG-IUS (Mirena) is a highly effective medical treatment with regression rates exceeding 90% for simple and complex hyperplasia — superior to cyclical progestogens. It avoids repeat D&C while providing reliable contraception.